Alavi, Maryam http://orcid.org/0000-0002-4130-1358
Grebely, Jason
Hajarizadeh, Behzad
Amin, Janaki
Larney, Sarah
Law, Matthew G.
George, Jacob
Degenhardt, Louisa
Dore, Gregory J.
Funding for this research was provided by:
Department of Health, Australian Government
NSW Ministry of Health
Sydney West Translational Cancer Research Centre (SW-TCRC) program HOTTer-West: HCC Outcome improvements Through Translational research in WESTern Sydney
Article History
Received: 6 July 2017
Accepted: 24 April 2018
First Online: 9 May 2018
Ethics approval and consent to participate
: This publication has complete approval from the NSW Population & Health Services Research Ethics Committee (Cancer Institute NSW reference number: 2013/11/493). The Ethics Committee granted a waiver of the usual requirement for the consent of the individual to the use of their health information in a research project, in line with the State Privacy Commissioner’s Guidelines for Research and the Health Records and Information Privacy Act 2002 (NSW) and the Guidelines approved under Section 95 of the Privacy Act 1988.
: J Grebely has received research support and is a consultant for Abbvie, Gilead Sciences and Merck. J Grebely has received research support from Bristol-Myers Squibb and Cepheid. ML has received research support from Merck, Bristol-Myers Squibb, Boehringer Ingelheim, Janssen-Cilag, Gilead Sciences, and ViiV HealthCare. ML has received consultancy and workshop fees from Gilead Sciences. ML has received Data Safety Monitoring Board Committee fees from Sirtex Pty Ltd. J George is on the speaker’s bureau for Gilead Sciences, Merck, Janssen, Roche, and Pharmaxis. J George is a member of advisory board for Gilead Sciences, Merck, Janssen, Bristol-Myers Squibb, Abbvie, Roche, GlaxoSmithKline, and Pharmaxis. J George has received travel support from Gilead Sciences, Merck, Bristol-Myers Squibb, Abbvie, and Roche. SL and LD have received untied educational grant funding from Indivior to examine naloxone for opioid overdose reversal (2015-2017), and OST use among chronic pain patients (2015-2016). GD has received research support and is a consultant for Gilead Sciences, Merck, and Janssen. GD has received research support from Bristol-Myers Squibb, Abbvie, and Roche. GD is on the speaker’s bureau for Gilead Sciences, Merck, Janssen, and Roche. GD is a member of advisory board for Gilead Sciences, Merck, Janssen, Bristol-Myers Squibb, Abbvie, Roche, GlaxoSmithKline, and Abbott Diagnostics. GD has received travel support from Gilead Sciences, Merck, Bristol-Myers Squibb, Abbvie, and Roche. MA and BH are members of the BMC Infectious Diseases editorial board. Other authors have no commercial relationships that might pose a conflict of interest in connection with this manuscript.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.